Disease · MONDO_0019810

toxic epidermal necrolysis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. toxic epidermal necrolysis. Diseases, record MONDO_0019810. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019810

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: toxic epidermal necrolysis; Open Targets
Open Targets ID: MONDO_0019810; Open Targets
Other names: SJS-TEN, TEN, toxic epidermolysis; Open Targets
NCI Thesaurus: C79777; NCI Thesaurus
Orphanet: ORPHA:95455; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 12 drugs, from ClinicalTrials.gov; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETANERCEPT	CHEMBL1201572	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CLOBETASOL	CHEMBL1201362	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
DARATUMUMAB	CHEMBL1743007	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
PALIFERMIN	CHEMBL1201821	Protein	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Early phase 1	ClinicalTrials.gov	2	2	2	Drugs and targets
ABROCITINIB	CHEMBL3655081	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK1	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Early phase 1	https://conductscience.org/library/genes/3716	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Early phase 1	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	2	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	1	Lymphocyte differentiation antigen CD38 inhibitor	Phase 1/2	https://conductscience.org/library/genes/952	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	1	Granulocyte colony stimulating factor receptor agonist	Phase 2/3	https://conductscience.org/library/genes/1441	Drugs and targets
FGFR2	Fibroblast growth factor receptor 2	1	Fibroblast growth factor receptor 2 agonist	Phase 1/2	https://conductscience.org/library/genes/2263	Drugs and targets
JAK2	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Early phase 1	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	1	Janus Kinase (JAK) inhibitor	Early phase 1	https://conductscience.org/library/genes/3718	Drugs and targets
RARA	Retinoic acid receptor	1	Retinoic acid receptor agonist	Unknown	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoic acid receptor	1	Retinoic acid receptor agonist	Unknown	https://conductscience.org/library/genes/5915	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01276314	Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions	Not applicable	135	2017-12-19	Drug Hypersensitivity	PREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT06474078	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN	Not applicable	20	2025-09-16	Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis	TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT02037347	Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis	Phase 1/2	1	2016-11-30	Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome	PALIFERMIN	Its record names the disease	ClinicalTrials.gov
NCT04651439	Severe Bullous Drug Eruption and Filgrastim	Phase 2/3	42		Rare Diseases, Toxic Epidermal Necrolyses	FILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT06119490	Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis	Early phase 1	30		Toxic Epidermal Necrolysis	ABROCITINIB, METHYLPREDNISOLONE, TOFACITINIB	Its record names the disease	ClinicalTrials.gov
NCT07110662	New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.	Phase 1/2	9		Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)	DARATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02987257	NATIENS: Optimal Management and Mechanisms of SJS/TEN	Phase 3	2		Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00372723	Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)	Phase 2	0		Toxic Epidermal Necrolysis	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01256489	Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)	Phase 1/2	0		Stevens-Johnson Syndrome, Corneal Blindness	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02319616	Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis	Phase 1/2	0		Toxic Epidermal Necrolysis	CLOBETASOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24928706	RESULT	1	PubMed
17919775	RESULT	1	PubMed
29400697	DERIVED	1	PubMed
26297574	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019810

GET https://conductscience.org/api/diseases/v1/MONDO_0019810/drugs

API reference For AI assistants